THUYA OCCIDENTALIS BOIRON XMK GRAN. RÉCIP. UNIDOSE - interactions (all)

The serum concentration of Idarubicin can be decreased when it is combined with Ampicillin.
The metabolism of Dutasteride can be decreased when combined with Doxycycline.
The risk or severity of adverse effects can be increased when Cilazapril is combined with Naproxen.
The risk or severity of adverse effects can be increased when Propoxycaine is combined with Cyclizine.
The serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.
Hydracarbazine may increase the hypotensive activities of Cilazapril.
The metabolism of Antipyrine can be decreased when combined with Zafirlukast.
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortisone acetate.
Barbital may increase the hypotensive activities of Penbutolol.
The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.
The serum concentration of Saxagliptin can be increased when it is combined with Diltiazem.
The risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil.
Atenolol may increase the hypotensive activities of Rituximab.
Perindopril may increase the hypotensive activities of Ferulic acid.
Lumiracoxib may increase the thrombogenic activities of Methallenestril.
The risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone.
The metabolism of Chlorzoxazone can be decreased when combined with Citalopram.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.
The risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Penbutolol.
Desoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.
The metabolism of Chlorphenamine can be decreased when combined with Tipranavir.
The therapeutic efficacy of Dienogest can be decreased when used in combination with Thiamylal.
The metabolism of Albendazole can be decreased when combined with Cyclosporine.
Carbaspirin calcium may decrease the excretion rate of Epirubicin which could result in a higher serum level.
The serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.
The metabolism of Proguanil can be decreased when combined with Tenofovir disoproxil.
The risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.
The risk or severity of adverse effects can be increased when Icatibant is combined with Tenofovir disoproxil.
The risk or severity of adverse effects can be increased when Candoxatril is combined with Diclofenac.
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Evening primrose oil.
The serum concentration of Vincristine can be increased when it is combined with Atazanavir.
Timolol may increase the orthostatic hypotensive activities of Levodopa.
The serum concentration of Ferulic acid can be increased when it is combined with Probenecid.
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Halothane.
The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Atazanavir.
The metabolism of Chlorzoxazone can be decreased when combined with Verapamil.
Ketoprofen may decrease the antihypertensive activities of Bisoprolol.
Zomepirac may decrease the antihypertensive activities of Oxprenolol.
The risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.
The risk or severity of adverse effects can be increased when Benzocaine is combined with Citalopram.
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perospirone.
The metabolism of Sitagliptin can be increased when combined with Rifapentine.
The serum concentration of Doxorubicin can be increased when it is combined with Ergotamine.
The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levocabastine.
Eprosartan may increase the hypotensive activities of Deserpidine.
Vilanterol may increase the QTc-prolonging activities of Eliglustat.
The metabolism of Levonorgestrel can be decreased when combined with Clemastine.
The serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Methazolamide.
Harmaline may increase the hypotensive activities of Perindopril.
Piretanide may increase the hypotensive activities of Cilazapril.
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Isoxicam.
The risk or severity of adverse effects can be increased when Heparin is combined with Collagenase clostridium histolyticum.
Rilmenidine may increase the hypotensive activities of Trichlormethiazide.
The risk or severity of adverse effects can be increased when Iproniazid is combined with Phenylpropanolamine.
The metabolism of Sertraline can be decreased when combined with Losartan.
The risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorothiazide.
Parecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.
The serum concentration of Dyphylline can be decreased when it is combined with Barbexaclone.
Aminosalicylic Acid may increase the hypoglycemic activities of Tolbutamide.
The risk or severity of adverse effects can be increased when Levorphanol is combined with Benzocaine.
The risk or severity of adverse effects can be increased when Semapimod is combined with Dexamethasone.
The metabolism of Loperamide can be decreased when combined with Terbinafine.
Methamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
Nebivolol may increase the orthostatic hypotensive activities of Prazosin.
The serum concentration of Norelgestromin can be decreased when it is combined with Artemether.
Indapamide may increase the QTc-prolonging activities of Azithromycin.
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid.
Hydrocortisone may increase the fluid retaining activities of Testosterone Propionate.
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vilanterol.
The serum concentration of Estradiol can be decreased when it is combined with Boceprevir.
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.
The risk or severity of adverse effects can be increased when Secobarbital is combined with Etoperidone.
The risk or severity of adverse effects can be increased when Indobufen is combined with Collagenase clostridium histolyticum.
The risk or severity of adverse effects can be increased when Enalapril is combined with Methazolamide.
The metabolism of Flunisolide can be decreased when combined with Ranolazine.
The metabolism of Vilanterol can be decreased when combined with Indinavir.
The risk or severity of adverse effects can be increased when Clofarabine is combined with Aliskiren.
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.
The metabolism of Dutasteride can be decreased when combined with Fluconazole.
The serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat.
Mizoribine may decrease the antihypertensive activities of Hydralazine.
Selexipag may increase the anticoagulant activities of Pentosan Polysulfate.
The metabolism of Temazepam can be decreased when combined with Verapamil.
The risk or severity of adverse effects can be increased when Flumethasone is combined with Rabies virus inactivated antigen, A.
The metabolism of Gemfibrozil can be decreased when combined with Erythromycin.
The metabolism of Clotiazepam can be decreased when combined with Verapamil.
The risk or severity of adverse effects can be increased when Cilazapril is combined with Semapimod.
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzocaine.
The risk or severity of adverse effects can be increased when Barnidipine is combined with Tolazoline.
The risk or severity of adverse effects can be increased when Clofarabine is combined with Reserpine.
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.
The risk or severity of adverse effects can be increased when Salicylamide is combined with Difluprednate.
The metabolism of Triazolam can be decreased when combined with Verapamil.
The risk or severity of adverse effects can be increased when Losartan is combined with Penbutolol.
The metabolism of Dihydrocodeine can be decreased when combined with Ketoconazole.
The risk or severity of adverse effects can be increased when Enalapril is combined with Cilazapril.
The therapeutic efficacy of Fluindione can be decreased when used in combination with Dydrogesterone.
Nialamide may increase the hypotensive activities of Felodipine.
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclosporine.
The risk or severity of adverse effects can be increased when Sacubitril is combined with Dapagliflozin.
The serum concentration of Testosterone can be increased when it is combined with Ivacaftor.
The risk or severity of adverse effects can be increased when Clonidine is combined with Methazolamide.
Dicoumarol may increase the anticoagulant activities of Troxerutin.
Temafloxacin may increase the hypoglycemic activities of Dapagliflozin.
The metabolism of Simvastatin can be decreased when combined with Paroxetine.
The risk or severity of adverse effects can be increased when Atropine is combined with Etorphine.
The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methylscopolamine bromide.
The metabolism of Sitagliptin can be decreased when combined with Saquinavir.
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Triprolidine.
The risk or severity of adverse effects can be increased when Lisinopril is combined with Meloxicam.
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.
The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Betamethasone.
The serum concentration of Cilostazol can be increased when it is combined with Miconazole.
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dimenhydrinate.
The metabolism of Carisoprodol can be decreased when combined with Cimetidine.
The risk or severity of adverse effects can be increased when Bifonazole is combined with Mibefradil.
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.
The serum concentration of Ulipristal can be decreased when it is combined with Griseofulvin.
The risk or severity of adverse effects can be increased when Fospropofol is combined with Dexbrompheniramine.
Ketorolac may decrease the antihypertensive activities of Levobunolol.
Mefloquine may increase the bradycardic activities of Metipranolol.
The metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir.
Selegiline may increase the hypoglycemic activities of Sitagliptin.
The metabolism of Nortriptyline can be decreased when combined with Atazanavir.
Nebivolol may increase the hypoglycemic activities of Glimepiride.
The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone propionate.